Article Details
Retrieved on: 2021-11-09 20:26:31
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Companies including CSL and Johnson & Johnson trialed anti-CD123 monoclonal antibodies only to stop work in response to lackluster efficacy.
Article found on: www.fiercebiotech.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here